IL124536A - Pharmaceutical compositions containing a glycine uptake antagonist - Google Patents

Pharmaceutical compositions containing a glycine uptake antagonist

Info

Publication number
IL124536A
IL124536A IL12453696A IL12453696A IL124536A IL 124536 A IL124536 A IL 124536A IL 12453696 A IL12453696 A IL 12453696A IL 12453696 A IL12453696 A IL 12453696A IL 124536 A IL124536 A IL 124536A
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
compositions containing
glycine uptake
antagonist
uptake antagonist
Prior art date
Application number
IL12453696A
Other languages
English (en)
Other versions
IL124536A0 (en
Original Assignee
Daniel C Javitt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21731199&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL124536(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daniel C Javitt filed Critical Daniel C Javitt
Publication of IL124536A0 publication Critical patent/IL124536A0/xx
Publication of IL124536A publication Critical patent/IL124536A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
IL12453696A 1995-12-07 1996-12-05 Pharmaceutical compositions containing a glycine uptake antagonist IL124536A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US836195P 1995-12-07 1995-12-07
PCT/US1996/019142 WO1997020553A1 (en) 1995-12-07 1996-12-05 Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists

Publications (2)

Publication Number Publication Date
IL124536A0 IL124536A0 (en) 1998-12-06
IL124536A true IL124536A (en) 2001-03-19

Family

ID=21731199

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12453696A IL124536A (en) 1995-12-07 1996-12-05 Pharmaceutical compositions containing a glycine uptake antagonist

Country Status (10)

Country Link
US (3) US5854286A (de)
EP (1) EP0871440B1 (de)
JP (3) JP2000501707A (de)
AT (1) ATE320804T1 (de)
DE (1) DE69635959T2 (de)
DK (1) DK0871440T3 (de)
ES (1) ES2260773T3 (de)
IL (1) IL124536A (de)
PT (1) PT871440E (de)
WO (2) WO1997020552A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE320804T1 (de) * 1995-12-07 2006-04-15 Daniel C Javitt Behandlung negativer und kognitiver symptome der schizophrenie mit antagonisten der glycinaufnahme
US6361957B1 (en) * 1999-08-03 2002-03-26 Glytech, Inc. Assay for D-serine transport antagonist and use for treating psychosis
US6355681B2 (en) * 1995-12-07 2002-03-12 Glytech, Inc. Glycine substitutes and precursors for treating a psychosis
US6191165B1 (en) 1996-05-31 2001-02-20 Allelix Neuroscience Inc. Pharmaceutical for treatment of neurological and neuropsychiatric disorders
US6001854A (en) * 1996-05-31 1999-12-14 Allelix Neuroscience Inc. Pharmaceutical for treating of neurological and neuropsychiatric disorders
ATE369848T1 (de) 1998-04-14 2007-09-15 Gen Hospital Corp Verwendung von d-serine oder d-alanine zur behandlung von schizophrenie
US6416975B1 (en) * 1998-11-12 2002-07-09 Gliatech, Inc. Human glycine transporter type 2
AU4361500A (en) * 1999-04-20 2000-11-02 Advocare International Llc Nutritional composition for improved cognitive performance
US6551993B1 (en) * 1999-08-16 2003-04-22 Thomas Jefferson University Partial agonists at the glycine modulatory site of the NMDA receptor for treating cognitive dysfunction
UA73749C2 (en) * 1999-11-01 2005-09-15 Diarylenines
TWI243173B (en) 1999-11-17 2005-11-11 Akzo Nobel Nv Spiro[2H-1-benzopyran-2,4'-piperidine] derivatives
SK287304B6 (sk) 2001-02-16 2010-06-07 Nps Pharmaceuticals, Inc. Substituované amínové deriváty ako inhibítory GlyT-1, farmaceutické prostriedky s ich obsahom, ich použitie, spôsob ich prípravy, ich medziprodukty a spôsob ich prípravy
US20020187544A1 (en) * 2001-04-05 2002-12-12 Wisconsin Alumni Research Foundation Uropathogenic E. coli D-serine detoxification operon
US20050164400A1 (en) * 2002-07-04 2005-07-28 Kenji Hashimoto Method of examining and diagnosing integration dysfunction syndrome
FR2843590B1 (fr) * 2002-08-14 2007-10-05 Prestwick Scient Capital Inc Derives de l'acide r(+)-2-amino-3-hydroxypropanoique a action glycinergique
US7160913B2 (en) * 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease
PT1587789E (pt) * 2003-01-16 2008-12-16 Acadia Pharm Inc Agonistas inversos selectivos para receptores 2a/2c da serotonina como agentes terapêuticos para doenças neurodegenerativas
IL154318A (en) * 2003-02-06 2010-05-31 Sarah Herzog Memorial Hospital Pharmaceutical compositions for the treatment of movement disorders
MXPA05011198A (es) 2003-04-30 2005-12-14 Lundbeck & Co As H Derivados de oxifenilo aromaticos y de sulfanilfenilo aromaticos.
BRPI0413587A (pt) * 2003-08-21 2006-10-17 Lundbeck & Co As H usos de um composto e de um inibidor de glyt-1, composição farmacêutica, kit, e, método para o tratamento de doença
US20070270403A1 (en) * 2003-12-04 2007-11-22 Broderick Patricia A Clozapine and Cocaine Effects on Dopamine and Serotonin Release in Nucleus Accumbens During Psychostimulant Behavior and Withdrawal
WO2005120487A2 (de) * 2004-06-11 2005-12-22 Egon Tech Präparat zur prophylaxe und therapie von stresszuständen, von funktionellen und organischen störungen des nervensystems und des stoffwechsels
WO2006000222A2 (en) * 2004-06-24 2006-01-05 H. Lundbeck A/S The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia
AU2005308538A1 (en) 2004-08-09 2006-06-01 Enrique Melendez Hevia Glycine as a diet supplement for the treatment of health problems that result from underlying metabolic disorders
SI1830833T1 (sl) * 2004-12-16 2010-05-31 Janssen Pharmaceutica Nv Kombinacija inhibitorja glicinskega transporterja GlyT in antipsihotika za zdravljenje simptomovshizofrenije in tudi njena priprava in njena uporaba
WO2008013860A2 (en) * 2006-07-28 2008-01-31 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use
CA2681506C (en) 2007-03-19 2016-05-24 Perry Peters Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
JP2010540454A (ja) * 2007-09-21 2010-12-24 アカディア ファーマシューティカルズ,インコーポレーテッド ピマバンセリンと他の薬剤との併用投与
IL188681A0 (en) * 2008-01-09 2008-12-29 Amino Acid Solutions Inc Pharmaceutical compositions and methods utilizing a d-amino acid
WO2010053976A2 (en) * 2008-11-04 2010-05-14 Mclean Hospital Corporation Drug-enhanced neurofeedback
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
WO2012065102A2 (en) * 2010-11-12 2012-05-18 Promentis Pharmaceuticals, Inc. S-t-butyl protected cysteine di-peptide analogs and related compounds
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
CN107848972B (zh) 2015-07-20 2021-06-18 阿卡蒂亚药品公司 用于制备n-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲及其酒石酸盐和多晶型c的方法
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2018118626A1 (en) 2016-12-20 2018-06-28 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
US11135211B2 (en) 2017-04-28 2021-10-05 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
RU2020100230A (ru) 2017-06-12 2021-07-13 Глитек Ллс. Лечение депрессии антагонистами nmda и антагонистами d2/5-ht2a или селективными антагонистами 5-нт2a
WO2019046167A1 (en) 2017-08-30 2019-03-07 Acadia Pharmaceuticals Inc. PIMAVANSERIN FORMULATIONS
CA3082834A1 (en) 2017-11-22 2019-05-31 Concert Pharmaceuticals, Inc. Deuterated analogs of d-serine and uses thereof
EP3737665A4 (de) * 2018-01-10 2021-11-03 XWPharma Ltd. Prodrugs von ketamin, zusammensetzungen und verwendungen davon
US20220087970A1 (en) * 2019-01-18 2022-03-24 The Johns Hopkins University Prevention of anesthetic-induced neurocognitive dysfunction
JP2023502966A (ja) * 2019-11-18 2023-01-26 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 脳の健康に使用するためのグルタチオンの増強のための組成物及び方法
WO2023018966A1 (en) 2021-08-13 2023-02-16 XWPharma Ltd. Pharmaceutical compositions and oral dosage forms of ketamine derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904681A (en) * 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
JPH07103018B2 (ja) * 1988-09-16 1995-11-08 武田薬品工業株式会社 精神分裂病治療剤
JP2757960B2 (ja) * 1988-10-17 1998-05-25 サントリー株式会社 (2R,3S,4S)−α−(カルボキシシクロプロピル)グリシン
US5187171A (en) * 1989-01-09 1993-02-16 G. D. Searle & Co. Use of a glycine b partial agonist as an antipsychotic
US5179085A (en) * 1989-03-15 1993-01-12 Warner-Lambert Company N-substituted α-amino acids and derivatives thereof having pharmaceutical activity
JPH03236315A (ja) * 1989-12-05 1991-10-22 Nippon Oil & Fats Co Ltd 抗精神病薬
US5260324A (en) * 1990-02-06 1993-11-09 G. D. Searle & Company Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5086072A (en) * 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
EP0614487A4 (de) 1991-11-12 1995-04-19 Synaptic Pharma Corp DNA, die für einen Glycin-Transporter kodiert und Anwendungen dafür.
US5428069A (en) * 1993-01-11 1995-06-27 The United States Of America As Represented By The Department Of Health & Human Services Treating cognition with, aminocyclopropanecarboxylic derivatives
US5656608B1 (en) * 1995-02-23 2000-09-26 Novartis Nutrition Ltd Amino acid compositions and methods of treatment using same
ATE320804T1 (de) * 1995-12-07 2006-04-15 Daniel C Javitt Behandlung negativer und kognitiver symptome der schizophrenie mit antagonisten der glycinaufnahme

Also Published As

Publication number Publication date
WO1997020552A1 (en) 1997-06-12
EP0871440A4 (de) 1999-01-20
WO1997020553A1 (en) 1997-06-12
DK0871440T3 (da) 2006-07-10
ATE320804T1 (de) 2006-04-15
JP5363152B2 (ja) 2013-12-11
DE69635959T2 (de) 2006-12-07
JP2000501707A (ja) 2000-02-15
US5854286A (en) 1998-12-29
PT871440E (pt) 2006-07-31
ES2260773T3 (es) 2006-11-01
EP0871440B1 (de) 2006-03-22
DE69635959D1 (de) 2006-05-11
US5837730A (en) 1998-11-17
EP0871440A1 (de) 1998-10-21
IL124536A0 (en) 1998-12-06
JP2013056918A (ja) 2013-03-28
JP2009167205A (ja) 2009-07-30
US6162827A (en) 2000-12-19

Similar Documents

Publication Publication Date Title
IL124536A (en) Pharmaceutical compositions containing a glycine uptake antagonist
CA1264740C (en) TETRAPYRROLE THERAPEUTIC AGENTS
MX9802564A (es) Composiciones de dipeptidos angioestaticas farmaceuticas y metodos para usar las mismas.
AU589176B2 (en) New tetrapyrrole therapeutic agents
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
PL327146A1 (en) Antagonists of the gonadotrophin liberating hormone
TW343198B (en) Cyclopeptides useful as adhesion inhibitors, process for the preparation thereof, and pharmaceutical composition containing them
MX9804850A (es) Antagonistas de hormona liberadora de gonadotropina.
ATE493998T1 (de) Pharmazeutische zusammensetzung mit einem exendin-4-peptid
MX163955B (es) Composicion farmaceutica de dihidrocodeina e ibuprofen
IL113625A0 (en) Amino acid derivatives processes for their preparation and pharmaceutical compositions containing them and their use
GR1003164B (el) Μεθοδοι και συνθεσεις για την βελτιωση των συμπτωματων της σηψης.
GR3029791T3 (en) Improved immunogenic compositions against human gastrin 17
EP0715857A3 (de) Pharmazeutische, oral anwendbare Zubereitungen enthaltend als Zerfallbeschleuniger eine wasserlösliche Aminosäure
GR3026369T3 (en) Pharmaceutical preparation containing an uricosuric and an excitatory amino acid antagonist.
HK1032542A1 (en) Combination for the treatment of alcohol dependence containing an opioid antagonist and nmda receptor complex modulator
MX9703642A (es) Metodos para el tratamiento de esclerosis multiple utilizando analogos de peptido en la posicion 91 de la proteina basica de mielina humana.
MY124560A (en) Amino acid compositions and use thereof in immunosuppression
ES2099021A1 (es) Composicion farmaceutica que tiene actividad analgesica.
DE69213935D1 (en) Neue heterocyclische carbonsäuren
NZ332655A (en) Pharmaceutical compositions containing diclofenac and alkali metal bicarbonates
MX9708557A (es) Nuevo uso farmacologico de los antagonistas del receptor aii.
MX9702253A (es) Nuevos estrenos para inducir efectos hipotalamicos
YU40398A (sh) Kompozicija nazalnog spreja za davanje sredstva za lečenje odloženog napada emezisa
IE831399L (en) Pharmaceutical composition containing meptazinol and¹ibuprofen.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees